Urokinase and Dornase alfa + Urokinase
Phase 2/3UNKNOWN 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pleural Empyema
Conditions
Pleural Empyema
Trial Timeline
Oct 1, 2007 → Oct 1, 2009
NCT ID
NCT00502632About Urokinase and Dornase alfa + Urokinase
Urokinase and Dornase alfa + Urokinase is a phase 2/3 stage product being developed by Roche for Pleural Empyema. The current trial status is unknown. This product is registered under clinical trial identifier NCT00502632. Target conditions include Pleural Empyema.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00502632 | Phase 2/3 | UNKNOWN |
Competing Products
20 competing products in Pleural Empyema